What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials

Present Algorithms and Future Treatments for Alzheimer’s Disease

(2019) George T. Grossberg et al.   JOURNAL OF ALZHEIMERS DISEASE

Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia

(2019) et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease

(2019) Michael F. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cerebral changes improved by physical activity during cognitive decline: A systematic review on MRI studies

(2019) Alexa Haeger et al.   NeuroImage-Clinical

The “rights” of precision drug development for Alzheimer’s disease

(2019) Jeffrey Cummings et al.   Alzheimers Research & Therapy

Effect of Long-Term Omega 3 Polyunsaturated Fatty Acid Supplementation with or without Multidomain Lifestyle Intervention on Muscle Strength in Older Adults: Secondary Analysis of the Multidomain Alzheimer Preventive Trial (MAPT)

(2019) Yves Rolland et al.   Nutrients

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise

(2018) Christopher H. van Dyck   BIOLOGICAL PSYCHIATRY

Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated

(2018) John L Robinson et al.   BRAIN

Clinical Trials for Disease-Modifying Therapies in Alzheimer’s Disease: A Primer, Lessons Learned, and a Blueprint for the Future

(2018) Jeffrey Cummings et al.   JOURNAL OF ALZHEIMERS DISEASE

Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer’s Disease

(2018) Elizabeth C. Mormino et al.   JOURNAL OF ALZHEIMERS DISEASE

Homocysteine and Dementia: An International Consensus Statement

(2018) A. David Smith et al.   JOURNAL OF ALZHEIMERS DISEASE

World Wide Fingers will advance dementia prevention

(2018) Miia Kivipelto et al.   LANCET NEUROLOGY

ABBY

(2018) Jeffrey L. Cummings et al.   NEUROLOGY

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

(2018) Michael F. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

(2018) Lawrence S. Honig et al.   NEW ENGLAND JOURNAL OF MEDICINE

Beneficial Effect of Multidomain Cognitive Training on the Neuropsychological Performance of Patients with Early-Stage Alzheimer’s Disease

(2018) Anastasia Nousia et al.   NEURAL PLASTICITY

A Randomized Controlled Trial of High-Dose Vitamin D2 Followed by Intranasal Insulin in Alzheimer's Disease

(2018) Mark S. Stein et al.   JOURNAL OF ALZHEIMERS DISEASE

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

(2018) Stephen Salloway et al.   Alzheimers Research & Therapy

Systematic Multi-Domain Alzheimer’s Risk Reduction Trial (SMARRT): Study Protocol

(2018) Kristine Yaffe et al.   JOURNAL OF ALZHEIMERS DISEASE

The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset

(2017) Francesco Panza et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer’s Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients

(2017) Lídia Blanco-Silvente et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Presenilin-1 mutations and Alzheimer’s disease

(2017) Raymond J. Kelleher et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Health-related quality of life in a multidomain intervention trial to prevent cognitive decline (FINGER)

(2017) T.E. Strandberg et al.   European Geriatric Medicine

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

(2017) Susanne Ostrowitzki et al.   Alzheimers Research & Therapy

Vitamin D deficiency as a risk factor for dementia: a systematic review and meta-analysis

(2017) Isolde Sommer et al.   BMC Geriatrics

FREE AND CUED SELECTIVE REMINDING TEST AS AN INCLUSION CRITERION FOR EARLY ALZHEIMER'S DISEASE CLINICAL TRIAL POPULATIONS

(2016) Janice Smith et al.   Alzheimers & Dementia

SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR F-18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A β-AMYLOID PLAQUE-SPECIFIC ANTIBODY, IN ALZHEIMER’S DISEASE (AD)

(2016) Michael C. Irizarry et al.   Alzheimers & Dementia

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

(2016) Eric R. Siemers et al.   Alzheimers & Dementia

Genomic variants, genes, and pathways of Alzheimer's disease: An overview

(2016) Adam C. Naj et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS

The amyloid hypothesis of Alzheimer's disease at 25 years

(2016) Dennis J Selkoe et al.   EMBO Molecular Medicine

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer’s disease

(2016) Mark Brody et al.   JOURNAL OF ALZHEIMERS DISEASE

Sex and the development of Alzheimer's disease

(2016) Christian J. Pike   JOURNAL OF NEUROSCIENCE RESEARCH

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies

(2016) Lon R. White et al.   NEUROLOGY

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

(2016) Veronika Logovinsky et al.   Alzheimers Research & Therapy

Advances in Alzheimer’s Disease Drug Development

(2015) Michael S Rafii et al.   BMC Medicine

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial

(2015) Tiia Ngandu et al.   LANCET

Multiple pathologies are common and related to dementia in the oldest-old

(2015) Claudia H. Kawas et al.   NEUROLOGY

Menopause, obesity and inflammation: interactive risk factors for Alzheimer’s disease

(2015) Amy Christensen et al.   Frontiers in Aging Neuroscience

Targeting Prodromal Alzheimer Disease With Avagacestat

(2015) Vladimir Coric et al.   JAMA Neurology

Alzheimer's disease

(2015) Colin L. Masters et al.   Nature Reviews Disease Primers

Moderate-Intensity Physical Activity, Hippocampal Volume, and Memory in Older Adults With Mild Cognitive Impairment

(2014) H. Makizako et al.   JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials

(2014) Reisa Sperling et al.   NEURON

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer's disease

(2013) Mark Forman et al.   Alzheimers & Dementia

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

(2013) Parminder Raina et al.   ANNALS OF INTERNAL MEDICINE

Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis

(2013) A. C. Tricco et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

The effect of exercise interventions on cognitive outcome in Alzheimer's disease: a systematic review

(2013) Nicolas Farina et al.   INTERNATIONAL PSYCHOGERIATRICS

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

(2013) Chia-Chen Liu et al.   Nature Reviews Neurology

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease

(2013) Chris G. Parsons et al.   NEUROTOXICITY RESEARCH

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

(2013) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy

(2013) Alireza Atri et al.   Alzheimers Research & Therapy

Neuropathological Alterations in Alzheimer Disease

(2013) A. Serrano-Pozo et al.   Cold Spring Harbor Perspectives in Medicine

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease

(2012) Henrik Zetterberg   ARCHIVES OF NEUROLOGY

Injury markers predict time to dementia in subjects with MCI and amyloid pathology

(2012) I. A. van Rossum et al.   NEUROLOGY

Total daily physical activity and the risk of AD and cognitive decline in older adults

(2012) A.S. Buchman et al.   NEUROLOGY

Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease

(2012) Robert Howard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current and future treatments for Alzheimer’s disease

(2012) Konstantina G. Yiannopoulou et al.   Therapeutic Advances in Neurological Disorders

Lack of Evidence for the Efficacy of Memantine in Mild Alzheimer Disease

(2011) Lon S. Schneider   ARCHIVES OF NEUROLOGY

Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease

(2011) Bradley T. Hyman   ARCHIVES OF NEUROLOGY

A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people

(2011) T. Kwok et al.   CLINICAL NUTRITION

Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies

(2011) C. Harrington et al.   Current Alzheimer Research

Neurodegenerative diseases and neuroprotection: current views and prospects

(2011) André Nieoullon   Journal of Applied Biomedicine

Alzheimer's disease: rapid and slow progression

(2011) C. J. Thalhauser et al.   Journal of the Royal Society Interface

Physical Exercise at Midlife and Risk of Dementia Three Decades Later: A Population-Based Study of Swedish Twins

(2011) R. Andel et al.   JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

The projected effect of risk factor reduction on Alzheimer's disease prevalence

(2011) Deborah E Barnes et al.   LANCET NEUROLOGY

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

(2011) M. Sano et al.   NEUROLOGY

Does physical activity influence semantic memory activation in amnestic mild cognitive impairment?

(2011) J. Carson Smith et al.   PSYCHIATRY RESEARCH-NEUROIMAGING

Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease

(2010) Eric R. Siemers et al.   CLINICAL NEUROPHARMACOLOGY

Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2010) Michael Gold et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Bapineuzumab

(2010) Geoffrey A Kerchner et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Amyloid-Independent Mechanisms in Alzheimer's Disease Pathogenesis

(2010) S. W. Pimplikar et al.   JOURNAL OF NEUROSCIENCE

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe

(2010) H. H. Feldman et al.   NEUROLOGY

Predicting progression of Alzheimer's disease

(2010) Rachelle S Doody et al.   Alzheimers Research & Therapy

Current Alzheimer's disease clinical trials: Methods and placebo outcomes

(2009) Lon S. Schneider et al.   Alzheimers & Dementia

Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia

(2009) Lori A. Daiello et al.   American Journal Geriatric Pharmacotherapy

Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials

(2009) Bengt Winblad et al.   CURRENT MEDICAL RESEARCH AND OPINION

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

(2009) Clifford R Jack et al.   LANCET NEUROLOGY

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY

Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease

(2008) Adam S. Fleisher et al.   ARCHIVES OF NEUROLOGY

High-Dose B Vitamin Supplementation and Cognitive Decline in Alzheimer Disease

(2008) Paul S. Aisen   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial

(2008) AD Collaborative Group   LANCET NEUROLOGY